

Wednesday 6th October 2021

Dear Liz and team,

Many thanks for the nomination news for SENISCA, we are extremely pleased! We have had quite a few very positive news updates since we submitted our application, so it would be ideal if you could also bear these in mind for the overall judging and selection process. Please see below, any questions then please don't hesitate to contact me on 07867 505 272.

Best wishes, Kirsty

1. Hello Tomorrow competition

SENISCA have been selected to showcase in Paris, from over 4,000 applications for the **Global Hello Tomorrow Deep Tech Pioneers competition**. Hello Tomorrow is a start-up competition which promises to unlock the power of deep tech to solve our toughest global challenges. Members of the SENISCA team will represent SENISCA at the Investor Day pitch event and the Global Summit, taking place in Paris on 1st- 3rd December 2021.

2. Proteomass Scientific Society lifetime career award

A huge congratulations to Lorna Harries, SENISCA's Chief Scientific Officer, who has recently been awarded the **Proteomass Scientific Society lifetime career award** for our 'pioneering work to link splicing with senescence.' Lorna was honoured to receive this award which celebrates her underpinning research identifying dysregulation of alternative splicing as a new, and druggable, hallmark of ageing.

3. Innovate UK Global Cooperation Feasibility Study

SENISCA was delighted to hear the news in early October 2021, that we have been awarded a competitively assessed £30,000 Innovate UK grant, as part of **Innovate UK's Global Cooperation Feasibility programme**. This provides funding for SENISCA to attend sector relevant networking events, increase global visibility, and meet with potential future pharmaceutical partners.

4. Team expansion

SENISCA formalised the appointment of the following new Board Directors and Scientific Advisory Board members during October 2021;

- **Scott Beattie**, ex CEO of Elizabeth Arden and current Vice-Chair of Revlon, who will join SENISCA's Board of Directors to oversee commercial strategy relating to our skin-ageing co-development programme,
- **Richard Haycock** (CEO QantX ventures) and **Sir Richard Olver** (previously Chairman BAE Systems and Deputy Chief Executive for BP) join the board as Investor Director representatives,
- **Steve Wilson** and **Jessica Cale**, from the Centre for Molecular Medicine and Innovative Therapeutics (Murdoch University), join SENISCA in Scientific Advisory Board roles relating to Oligonucleotide synthesis and design.